Osteoprotegerin (OPG) ELISA Assay Kit

$660.00

The Eagle Biosciences Human Osteoprotegerin (OPG) ELISA Assay Kit (enzyme-linked immunoassay kit) is intended for the quantitative determination of human osteoprotegerin levels in serum or plasma samples. The Eagle Biosciences Human Osteoprotegerin (OPG) ELISA Assay Kit is for research use only and not to be used in diagnostic procedures.

SKU: BI-20403 Categories: , ,

Osteoprotegerin (OPG) ELISA Assay Kit

For Research Use Only

Size: 1×96 wells
Sensitivity: LOD: (0 pmol/l + 3 SD): 0.07 pmol/l; LLOQ: 0.08 pmol/l
Dynamic Range: 0 to 20 pmol/l
Incubation Time: 5.5 hours
Sample Type: Serum, plasma (EDTA, heparin, citrate)
Sample Size: 20 µL
Controls Included

Product Developed and Manufactured in Austria by Biomedica

Unit conversion: 1 pg/ml = 0.05 pmol/l (MW: 19.9 kD)

Additional Information

Assay Background


Osteoprotegerin (OPG) or Osteoclast inhibitory factor (OCIF) is a glycoprotein of the TNF receptor superfamily 11b (gene name TNFRSF11B) https://www.uniprot.org/uniprot/O00300. OPG is synthesized as a monomer of 380 amino acids and is assembled as a homodimer within the cell and then secreted mainly as a disulfide-linked homodimer into the extracellular compartment. OPG is produced by many different tissues and cell types including osteoblasts. OPG is a negative regulator of bone resorption by acting as decoy receptor for RANKL, thus neutralizing its function in osteoclastogenesis. This glycoprotein is also involved in the regulation of vascular calcification.

Assay Procedure


  1. Pipette 150 µl ASYBUF (Assay Buffer, red cap) into each well.
  2. Add 20 µl STD/SAMPLE/CTRL (Standard/Sample/Control) in duplicate into respective wells, swirl gently.
  3. Add 50 µl AB (biotinylated anti OPG antibody, green cap) into each well, swirl gently.
  4. Cover tightly and incubate for 4 hours at room temperature (18-24°C).
  5. Aspirate and wash wells 5x with 300 µl diluted WASHBUF (Wash buffer). After final wash, remove remaining WASHBUF by strongly tapping plate against paper towel.
  6. Add 200 µl CONJ (Conjugate, amber cap) into each well.
  7. Cover tightly and incubate for 1 hour at room temperature (18-24°C).
  8. Aspirate and wash wells 5x with 300 µl diluted WASHBUF (Wash buffer). After final wash, remove remaining WASHBUF by strongly tapping plate against paper towel.
  9. Add 200 µl SUB (Substrate, blue cap) into each well.
  10. Incubate for 30 min at room temperature (18-24°C) in the dark.
  11. Add 50 µl STOP (Stop solution, white cap) into each well, swirl gently.
  12. Measure absorbance immediately at 450 nm with reference 630 nm, if available.

osteoprotegerin-opg-elisa-assay-kit-1

Typical Standard Curve


osteoprotegerin-opg-elisa-assay-kit-2

Expected Values


Values from apparently healthy individuals:

  • Median serum (n=60): 2.7 pmol/l
  • Median EDTA plasma (n=6): 2.2 pmol/l
  • Median heparin plasma (n=7): 2.3 pmol/l
  • Median citrate plasma (n=5): 2.3 pmol/l

It is recommended to establish the normal range for each laboratory.

Manual

Product Manual


Publications

Citations


  • TSzulc P et al.: Cortical Bone Status Is Associated with Serum Osteoprotegerin Concentration in Men: The STRAMBO Study. J Clin Endocrinol Metab (2011), 96: 2216-2226.
  • Samelson EJ et al.: Increased Plasma Osteoprotegerin Concentrations are Associated with Indices of Bone Strength of the Hip. J Clin Endocrinol Metab (2008), 93: 1789-1795.
  • Terpos E et al.: The Clinical Significance of Serum Markers of Bone Turnover in NSCLC Patients: Surveillance, Management and Prognostic Implications. Anticancer Res (2009), 29: 1651-1657.
  • Madarász E et al.: Osteoprotegerin Levels in Women With Prior Gestational Diabetes Mellitus. Diabetes Care (2009), 32: e5.
  • Kearns AE et al.: Receptor Activator of Nuclear Factor B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease. Endocr Rev (2008), 29: 155-192.
  • Pepene C et al.: Circulating osteoprotegerin and soluble receptor activator of nuclear factor B ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction. Eur J Endocrinol (2011),164: 61-68.
  • Tuyl van L.: Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. Ann Rheum Dis (2010), 69: 1623-1628
  • Anastasilakis AD et al.: Evaluation of Bone Mineral Density, Bone Metabolism, Osteoprotegerin and Receptor Activator of the NF B Ligand Serum Levels During Treatment with Infliximab in Patients with Rheumatoid Arthritis. Eur J Endocrinol (2008), 158: 411-415.
  • Faienza F et al.: Osteoclastogenesis in Children with 21-Hydroxylase Deficiency on Long-Term Glucocorticoid Therapy: The Role of Receptor Activator of Nuclear Factor- B Ligand/Osteoprotegerin Imbalance. J Clin Endocrinol Metab (2009), 94: 2269-2276.
  • Park JS et al.: Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitusEur J Endocrinol (2011), 164: 69-74.
  • Nybo M et al.: Rosiglitazone decreases plasma levels of osteoprotegerin in a randomized clinical trial with type 2 diabetes patients. Basic Clin Pharmacol Toxicol (2011),109(6): 481-485.
  • Semb A et al.: Osteoprotegerin and Soluble Receptor Activator of Nuclear Factor- B Ligand and Risk for Coronary Events. A Nested Case-Control Approach in the Prospective EPIC-Norfolk Population Study. 1993-2003. Arterioscler Thromb Vasc Biol (2009), 29: 975-980.
  • Svensson M et al.: Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study. Nephrol Dial Transplant (2011), 10.1093/ndt/gfr694.
  • Stavroulopoulos A et al.: Evolution of coronary artery calcification in patients with chronic kidney disease Stages 3 and 4, with and without diabetes. Nephrol Dial Transplant (2011), 26: 2582-2589.
  • Lieb W et al.: Biomarkers of the Osteoprotegerin Pathway: Clinical Correlates, Subclinical Disease, Incident Cardiovascular Disease, and Mortality. Arterioscler Thromb Vasc Biol (2010): 30: 1849-1854.
  • Ueland T et al.: Osteoprotegerin Predicts Progression of Chronic Heart Failure: Results From CORONA. Circ Heart Fail (2011): 4: 145-152.